Nuvectis Pharma, Inc.
About Nuvectis Pharma, Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$26.4M
- Total assets
- $31.7M
- Market cap
- $253.1M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$27.6M
- Net income
- -$26.4M
- EPS (basic)
- $-1.32
- EPS (diluted)
- $-1.32
Balance sheet
- Total assets
- $31.7M
- Current assets
- $31.7M
- Total liabilities
- $13.3M
- Current liabilities
- $13.3M
- Shareholders’ equity
- $18.4M
Cash flow
- Operating cash flow
- -$16.0M
- Investing cash flow
- -$13.1M
- Financing cash flow
- $29.1M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $253.1M
- EPS (diluted)
- $-1.32
- Shares outstanding
- 26.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 4, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.4M.
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nuvectis Pharma, Inc..
Write a review
News about Nuvectis Pharma, Inc.
News & sentiment via Polygon.io
